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Abstract The aim of this study was to investigate the
inhibitory effect of a siRNA cocktail targeting Vascular
endothelial growth factor (VEGF) and Human epidermal
growth factor receptor 2 (HER2) on cell proliferation,
induced apoptosis and the expression of VEGF and HER2
in human gastric carcinoma cell. The silencing rate of pre-
designed siRNAs that targeted VEGF and HER2 was
detected by Real-time Quantitative PCR (RT-QPCR) ana-
lysis. Furthermore, the best silencing siRNA that targeted
VEGF and HER2 was prepared as a cocktail to co-
knockdown VEGF and HER2 expression at both mRNA
and protein levels which were detected by RT-QPCR and
Western blot analysis. Cell proliferation inhibition rates
were determined by CCK8 assay. The effect of siRNA
cocktail on cell apoptosis was determined by flow cytom-
etry. The migration inhibition of siRNA cocktail was
analyzed by wound-healing assay. The ability of VEGF to
induce endothelial cells to proliferate was examined in
HUVECs by the method of tube formation assay. The pre-
designed siRNAs could inhibit VEGF and HER2 mRNA
level. siRNA cocktail, and co-downregulation of VEGF
and HER2 result in significant inhibition of gastric cancer
growth and migration in vitro. The inhibition of VEGF and
HER2 expressions can induce apoptosis of SGC-7901 cells.
Keywords siRNA  siRNA cocktail  VEGF 
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Introduction
Gastric cancer is one of the most common types of cancer
and the second most common cause of cancer-related
mortality worldwide [1, 2]. At present, conventional ther-
apies for gastric cancer include resection, chemotherapy,
and radiotherapy, but these measures are non-curative for
those patients who are diagnosed with advanced gastric
cancer. As a result, new therapeutic methods are needed
urgently for more effective treatment of this aggressive
malignancy. Biological therapy based on the molecular-
targeted therapy is an emerging technology for gastric
cancer to improve the quality of life and survival of patients.
RNA interference (RNAi) is a post-transcriptional pro-
cess triggered by double-stranded RNA which leads to
gene silencing in a sequence-specific manner through
degradation of the corresponding mRNA.
Human epidermal growth factor receptor 2 (HER2), also
known as ErbB-2, is a protein that in humans is encoded by
the ERBB2 gene. HER2 is a member of the epidermal
growth factor receptor (EGFR/ErbB) family. Its activation
leads to a cascade of events promoting rapid cell growth,
differentiation, survival, and migration [3]. Overexpression
of HER2 has been found to induce tumorigenesis and to be
involved in the pathogenesis of gastric cancer [4]. Ampli-
fication and overexpression of HER2 play an important
role in disease initiation, progression, and metastasis, and
have been associated with a worse prognosis in patients
with gastric cancers [5].
Vascular endothelial growth factor (VEGF) is a signal
protein produced by cells that stimulates vasculogenesis
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and angiogenesis. It is the key mediator of angiogenesis in
cancer, in which it is up-regulated by oncogene expression,
a variety of growth factors, and also hypoxia [6]. And
VEGF is correlated with gastric cancers, especially in the
patients with advanced gastric cancer which significantly
lowers survival rates. VEGF can serve as a pertinent
prognostic indicator both in early and advanced gastric
cancer [7]. Bevacizumab, a monoclonal antibody targeting
VEGF-A, was used to inhibit advanced gastric cancer
combined with chemotherapy [8].
In the present study, we intended to use siRNA cocktail
therapy which targets VEGF and HER2 gene for the
treatment of gastric cancer. Pre-designed VEGF and HER2
siRNAs were screened in gastric cancer cells, and the best
siRNA targets were used as cocktail to inhibit the growth
and induced apoptosis of SGC-7901 gastric cancer cell.
Materials and methods
Cell culture
Gastric cancer SGC-7901 and HUVEC cell lines were pur-
chased from the Institute of Cell Biology, Chinese Academy
of Sciences. The cells were cultured in Dulbecco modified
Eagle medium (DMEM) (Gibco, USA) supplemented with
10 % fetal bovine serum (FBS) (Gibco, USA), 100 U/ml
penicillin, and 100 lg/ml streptomycin (Invitrogen, USA) at
37 C in a humidified incubator with 5 % CO2.
siRNA sequences and transfection in vitro
The sequence of VEGF and HER2 was obtained from Gen-
Bank (Assession No. NM_001171623 and NM_001005862).
According to an optimization principle of siRNA design
methods [9], we designed 4 sequence-specific siRNAs tar-
geting either VEGF or HER2 in length of 19 nt with dTdT
30overhang. Meanwhile, negative control siRNA (NC-siR)
that has no homology with human genome was designed as
negative control. The sequences used for the experiments are
shown in Table 1. All chemically synthesized siRNAs were
obtained from Biomics Biotech (China).
All the above siRNAs were mixed into Lipofectamine
TM
2000 (Invitrogen, USA) and transfected according to the
manufacturer’s instruction. After 6 h at 37 C, the DMEM
was replaced with complete growth medium (DMEM with
10 % FBS). The cells without siRNA transfection were
used as untreated control.
RT-QPCR analysis
The mRNAs were isolated from SGC-7901 cells using
TurboCapture 96 mRNA Kit (QIAGEN, USA) 48 h post-
transfection, and then were submitted to a 25 ll PCR
reaction in the presence of 12.5 ll of 29 Master Mix, 1 ll
of each forward and reverse primers mix (10 lM each),
0.5 ll of 509 SYBR Green I and 4 ll mRNA as template.
The PCR mixtures were first subjected to reverse tran-
scription for 30 min at 42 C and initially denatured for
5 min at 95 C, and then to 45 cycles of amplification with
the following cycling condition: 20 s at 95 C, 30 s at
58 C, and 30 s at 72 C. The primer pairs for each gene
were designed with Primer Premier 5.0 software; glycer-
aldehyde-3-phosphate dehydrogenase served as an internal
control for PCR. Sequences of all the primers (Biomics
Biotech, China) are shown in Table 2.
Western blot analysis
The protein expression levels of SGC-7901 cells were
measured by Western Blot analysis. Cells were plated at a
concentration of 1 9 106 cells per well in 6-well plates,
and grown for 24 h until they reached 70–80 % confluence.
The cells were divided into five groups with different
treatments at final concentration of 20 nM: VEGF_siR4,
HER2_siR3, siRNA cocktail (VEGF_siR4 mixed with
HER2_siR3 at equal concentration), NC_siR, and without
treated as untreated group. Cells were harvested at 48 h
after transfection and lysed in ice-cold cell RIPA buffer
(Beyotime, China). The amount of total cell proteins was
determined by BCA kit (Beyotime, China). 20 lg of pro-
teins were separated on SDS-PAGE and electroblotted onto
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PVDF membranes (Millipore, USA). Then the membranes
were blocked with 5 % skim milk in TBST (10 mM Tris–
HCl, 150 mM NaCl, 0.25 % Tween 20, pH 7.5) at room
temperature for 2 h, following incubated overnight with
primary antibody of polyclonal rabbit-anti-human VEGF
(Gene Biotech, USA; 1:200 dilution) and mouse-anti-
hunan HER2 (Santa Cruz Biotech, USA; 1:200 dilution),
with mouse-anti-human b-actin (Santa Cruz Biotech, USA;
1:200 dilution) as control. After washing with TBST, the
membranes were incubated with secondary antibody (Santa
Cruz Biotech, USA; goat anti-rabbit IgG-HRP with 1:1,000
dilution for VEGF; goat anti-mouse IgG-HRP with 1:2,000
dilution for HER2 and b-actin) for 2 h at room tempera-
ture. After three washes with TBST, proteins were visu-
alized by chemiluminescence. The relative amount of
proteins on the blots was determined by Image J software.
Cell proliferation assay
SGC-7901 cells proliferation was measured by Cell
Counting Kit-8 detection kit (Dojindo, Japan). Cells were
seeded at a concentration of 5 9 103 cells per well in
96-well plates. All experiments were conducted in tripli-
cate. After grown for 24 h resulted in about 70–80 %
confluence, cells were performed with different treatments
as described above. At 24, 48, 72 and 96 h after transfec-
tion, CCK-8 solution was applied at 10 ll per well and
followed by 2-h incubation at 37 C. Absorbance values of








Fig. 1 The mRNA relative level of VEGF (a) and HER2 (b) with
pre-designed siRNAs treatments in SGC-7901 cells by RT-QPCR.
Values were given as mean ± SD of three separate experiments with
triplicate wells per condition. *P \ 0.01 compared with untreated and
NC_siR
Fig. 2 The mRNA relative level of VEGF (a) and HER2 (b) with
different treatments in SGC-7901 cells by RT-QPCR. Values were
given as mean ± SD of three separate experiments with triplicate
wells per condition. *P \ 0.01 compared with untreated, #P \ 0.05
compared with untreated
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all wells were then determined at 450 nm in Microplate
Reader (Bio-Rad, USA).
Wound-healing assay
Cells migration was measured by wound-healing assay.
SGC-7901 cells were seeded and transfected with siRNAs
as described above in 12-well plates at the density of
3 9 105 cells per well. After 48 h, wound was made
through confluent monolayer cells with a pipette tip and
cells were washed with PBS, DMEM medium without
adding FBS. Photographs of cells were taken at 0, 24, 48,
and 72 h to monitor cell movements.
FCM analysis
Annexin-V/propidium iodide (PI) double staining assay was
performed by using the Annexin V-FITC apoptosis detection
kit (Sigma-aldrich, USA) as described by the manufacture’s
instruction. Briefly, 1 9 106 cells per well after 48-h trans-
fection with various treatments described above were har-
vested and washed with PBS in 6-well plates. The cells were
washed with PBS twice and resuspended in 19 Binding
buffer, followed by incubated with Annexin V-FITC conju-
gate and PI for 15 min to protect from light at room temper-
ature. Cells were analyzed by flow cytometry (FCM) analysis
using BD CELLQuest software (BD Biosciences, USA).
Tube formation assay
The ability of endothelial cells to sprout new blood vessels
stimulated by pro-angiogenic factors released from the
gastric cancer cell was examined in HUVECs angiogenesis
in vitro model [10]. Briefly, 6 9 104 HUVECs were col-
lected, resuspended in a conditioned medium, which was
the supernatant of SGC-7901 with siRNAs post-transfected
for 48 h, seeded in 48-well plates that were coated with
100 ll of gelled matrigel (BD Biosciences, USA), and
cultured in a humidified 37 C/5 % CO2 incubator. After
incubation for 6 or 12 h, numbers of branching points were
counted. The data were obtained from triplicate wells
under each experimental condition at each time point.
Statistical analysis
All experiments were performed independently three times,
the results a were shown as mean values ± standard
deviation (SD), and statistical analyses were performed
using SPSS17.0 software. The statistical differences were
calculated using a standard one-way ANOVA and two-
tailed unpaired Student’s t test. P \ 0.05 was considered as
statistically significant. In all graphs, *, # indicates sig-
nificant difference.
Results
Inhibition effects of pre-designed siRNAs that target
VEGF and HER2
The mRNA levels were determined by RT-QPCR after
treatments with SGC-7901 cells for 48 h. As shown in
Fig. 1a, VEGF siRNAs inhibited the VEGF expression at
the mRNA level up to 75 % in comparison to the untreated
ones. And the silencing effects of HER2 siRNAs were
observed at mRNA level up to 73 % (Fig. 1b).
Fig. 3 The protein relative level of VEGF and HER2 with different
treatments in SGC-7901 cells by Western blot. Values were given as
mean ± SD of three separate experiments with triplicate wells per
condition. *P \ 0.05 VEGF protein relative level compared with
untreated and NC_siR, #P \ 0.05 HER2 protein relative level
compared with untreated and NC_siR
Fig. 4 Cell proliferation was analyzed by CCK8 assay. Growth curve of
SGC-7901 cells was shown for each treatment at 0, 24, 48, 72, and 96 h.
*P \ 0.01 compared with untreated, #P \ 0.05 compared with untreated
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Inhibition effects of siRNA cocktail targeting VEGF
and HER2 on mRNA and protein level
After treatments of siRNA cocktail and controls into SGC-
7901 cells for 48 h, the mRNA and protein level of VEGF
and HER2 was determined by RT-QPCR and Western blot.
As shown in Figs. 2 and 3, siRNA cocktail inhibited the
VEGF and HER2 expressions at the mRNA and protein
level, obviously in comparison to the untreated ones.
Meanwhile, HER2 was silenced by HER2_siR3, but VEGF
was also inhibited by it at mRNA level up to 47 %
(P \ 0.05), and the detection of protein expression was
confirmed by knockdown (Fig. 3).
Inhibition of cell proliferation by siRNA cocktail
targeting VEGF and HER2
The cell proliferation inhibition effects of siRNA cocktail
in SGC-7901 cells were detected by CCK8 assay. The
absorbance values of the SGC-7901 cells at 48, 72 and 96 h
Fig. 5 Cell migration inhibition
effects of targeting VEGF and/
or HER2 on SGC-7901. a The
cells with different treatments at
0, 24, 48, and 72 h (1009).
b Cell relative migration
distances in different time point
treatments were presented as
mean ± SD. *p \ 0.01,
#p \ 0.05 compared with
untreated and NC_siR
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post-transfection with siRNA cocktail and either
VEGF_siR4 or HER2_siR3 were significantly lower than
those of the untreated cells. There was no significant
difference between the growth of cells treated with
VEGF_siR4 and that of HER2_siR3. The cell proliferation
inhibition rate treated with siRNA cocktail showed a sig-
nificant decrease in cell proliferation compared with the
cells treated with either VEGF_siR4 or HER2_siR3 at 48,
72 and 96 h (Fig. 4).
Decrease of the cell migration ability by siRNA
cocktail targeting VEGF and HER2
Wound-healing assay was used to evaluate the migration
ability of SGC-7901 cells after different treatments. As
illustrated in Fig. 5a, the scratch caused in groups of
untreated and NC_siR nearly closed completely after 72 h,
but the cells in treatment with siRNA cocktail and
VEGF_siR4 or HER2_siR3 were not able to move toward
the center of the wound. As shown in Fig. 5b, siRNA
cocktail and VEGF_siR4 or HER2_siR3 all exhibited a
decrease in wound healing ability compared to the
untreated and NC_siR-treated cells (*P \ 0.01).
Cell apoptosis induced by siRNA cocktail that targeting
VEGF and HER2
Annexin V-FITC/PI double staining and FCM analysis
were performed to evaluate the ability of siRNA cocktail,
VEGF_siR4, or HER2_siR3 on inducing SGC-7901 cell
apoptosis. As Fig. 6 shows, treatment with siRNA cocktail
resulted in a significant increase of apoptosis compared
with that of untreated cells (p \ 0.05).
Influence of siRNA cocktail targeting VEGF and HER2
on tube formation
A HUVECs angiogenesis model was employed to evaluate
the tube formation of HUVECs stimulated by the condi-
tioned medium derived from SGC-7901 cells transfected
with siRNA cocktail, VEGF_siR4, HER2_siR3 and
NC_siR. As illustrated in Fig. 7, HUVECs which were
treated with siRNA cocktail, VEGF_siR4, HER2_siR3
were inhibited to form extensive and enclosed tube net-
works as compared with the untreated ones.
Discussion
In the present study, we found that siRNA cocktail silencing
VEGF and HER2 together could inhibit the proliferation and
migration of gastric cancer cell very well. On the other hand,
the cocktail could also promote apoptosis of gastric cancer cell.
HER2 was overexpressed in several cancers, such as
breast cancers [11], colon [12], bladder [13], ovarian [14],
endometrial [15], lung [16], uterine cervix [17], head and
neck [18], esophageal [19] etc. HER2 proteins have been
shown to form clusters in cell membranes that may play a
role in tumorigenesis [20, 21].
In recent years, HER2 was found overexpressed in
gastric cancer; it could be a new prognostic factor and a
novel therapeutic target [22, 23]. Some reports have shown
that siRNA-mediated knock-down of HER2 expression
resulted in decreased proliferation and induced apoptosis in
breast cancer cell SKBr3 and the ovarian cancer cell [24].
In this study, we also demonstrated that the siRNA tar-
geting HER2 could inhibit proliferation and induce apop-
tosis in SGC-7901 gastric cancer cells.
Generally, tumors do need to induce a new vascular
supply if they are to grow [25]. VEGF is widely expressed
by nearly all malignant tumors, and it acts on vascular
endothelial cells to induce vascular permeability and, in the
longer term, reprograms gene expression, leading to
Fig. 6 Cell apoptosis was detected by Annexin V-FITC/PI double
staining and FCM analysis. a Apoptosis rates were measured by FCM
analysis after AnnexinV/PI staining. b Percentage of dual-positive
(Annexin V and PI were positive) cells from three independent
experiments was quantified and presented as mean ± SD. *p \ 0.01
compared with untreated and NC_siR, #p \ 0.05 compared with
siRNA cocktail
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endothelial cell proliferation and migration in vitro, and
generation of new blood vessels in vivo. Moreover, a
variety of anti-tumor drugs that target VEGF-A or its
receptors had been demonstrated effectively [26, 27]. A
humanized antibody drug-bevacizumab against VEGF-A
prolongs the life of patients with advanced colon cancer by,
on average, 4–5 months, and then only when combined
with triple chemotherapy [28]. In fact, a recent editorial has
shown its limited effectiveness, serious side effects, and
high cost [29].
RNAi is a new approach for therapeutic treatment of
cancer, infectious diseases, and other diseases associated
with specific gene disorders, with more than 30 clinical trials
of RNAi-based drugs since the discovery of the mechanism
[30]. Furthermore, the siRNA conjugating with the delivery
system showed safety on the clinical trial [31]. The Anti-
VEGF siRNA had already been reported by many
researchers for the cancer treatment [24, 32, 33]. And, VEGF
is also overexpressed in advanced gastric cancer [7]. In the
study, we found that siRNA targeting VEGF could inhibit
gastric cancer cell proliferation and anti-angiogenesis better.
Using the siRNA cocktail targeting VEGF and HER-2 to
inhibit the proliferation and induce apoptosis of gastric
cancer cell is the first report by our study. Gastric cancer
cell SGC-7901 with overexpression of VEGF and HER2
was used as in vitro cancer model; the best siRNAs for
knockdown of the VEGF and HER2 were screened by RT-
QPCR. Furthermore, we prepared the siRNA cocktail of
best siRNAs, analyzed the cell treated with siRNA cocktail
and controls (including single siRNA targeting VEGF or
HER2 and negative control siRNA which has no homology
with human gene), and determined the cell proliferation,
migration, and apoptosis. Results displayed that siRNA
cocktail could silence the VEGF and HER2 better than
single siRNA simultaneously, and the inhibition of cell
proliferation, migration, and inducing apoptosis were good
effects by the treatment of siRNA cocktail. Concurrently,
the anti-angiogenesis had been evaluated on the HUVECs
angiogenesis model; result showed that HUVECs were
inhibited to form capillary tube-like structures on Matrigels
as compared with the untreated group after siRNAs trans-
fected (Fig. 7).
HER-2 could impact angiogenesis, and overexpression
of HER2 is correlated with up-regulation of VEGF in
breast cancer [34]. In the study, we also found that the
HER2 inhibition could induce down-regulation of VEGF,
but it does not vice versa in the gastric cancer cell, as
shown in Fig. 1. In summary, the use of siRNA cocktail
targeting VEGF and HER2 deserves further investigation
as a novel approach to gastric cancer therapy.
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